Inozyme Pharma (NASDAQ:INZY) Downgraded by Zacks Investment Research to Hold

Inozyme Pharma stock has undergone multiple analysts rating changes in the recent past.  Inozyme Pharma Downgraded by Zacks Investment Research on 10/14/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Buy.

Shares of Inozyme Pharma traded down -$0.16 on Wednesday, reaching $9.73. 0 shares of the stock traded hands, compared to its average volume of 143617. Shares of Inozyme Pharma were trading at $9.73 on Wednesday. The firm’s 50 day moving average is $13.69 and its 200 day moving average is $18.00.Inozyme Pharma has a 12 month low of $9.65 and a 12 month high of $29.46. While on yearly highs and lows, Inozyme Pharma’s today has traded high as $10.29 and has touched $9.65 on the downward trend. See More Analyst Rating at: RATING

Inozyme Pharma Earnings and What to expect: 

Inozyme Pharma last released its quarterly earnings results on August 11th, 2021. The reported ($0.53) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.04. Inozyme Pharma has generated ($5.11) earnings per share over the last year. Earnings for Inozyme Pharma are expected to decrease in the coming year, from ($2.29) to ($2.59) per share. Inozyme Pharma has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, November 11th, 2021 based off prior year’s report dates.

Earnings for Inozyme Pharma are expected to decrease in the coming year, from ($2.29) to ($2.59) per share. The P/E ratio of Inozyme Pharma is -1.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Inozyme Pharma is -1.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Inozyme Pharma has a P/B Ratio of 1.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Inozyme Pharma (NASDAQ:INZY) Moving Average Technical Analysis

5 day Moving Average is $10.00 And 5 day price change is -$0.63 (-6.08%)  with average volume for 5 day average is 94,980. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $11.41 and 20 day price change is -$2.82 (-22.47%) and average 20 day moving volume is 144,730. 50 day moving average is $13.69  and 50 day price change is -$6.85 ( -41.31%)  and with average volume for 50 days is : 96,180. 200 day moving average is $18.00  and 200 day price change is -$14.86 (-60.43%)  and with average volume for 200 days is : 69,465.

Other owners latest trading in Inozyme Pharma :

  • On 8/25/2021 shares held by Marshall Wace LLP were 40,202 which equates to market value of $0.69M and appx 0.00% owners of Inozyme Pharma
  • On 8/23/2021 shares held by Morgan Stanley were 42,754 which equates to market value of $0.73M and appx 0.00% owners of Inozyme Pharma
  • On 8/17/2021 shares held by Millennium Management LLC were 61,313 which equates to market value of $1.05M and appx 0.00% owners of Inozyme Pharma
  • In total Institutional ownership equates to Institutional Ownership Percentage: 83.61% for Inozyme Pharma

See More Analyst Rating at: RATING